Ind-Swift Labs Q1 FY27 Profit Jumps 2.04x YoY to ₹24.68 Cr; EBITDA Up 2.85x
Ind-Swift Laboratories reported robust Q1 FY27 results with operating EBITDA up 2.85x YoY to ₹33.32 crore and PAT up 2.04x YoY to ₹24.68 crore. EBITDA margin expanded by 1,258 bps to 17.91%. The company expects FY27 revenue growth exceeding 50% and a medium-term revenue CAGR of 20-25%.
The substantial increase in profitability, margin expansion, and positive future revenue guidance are significant developments that are likely to have a high impact on investor sentiment and the company's stock performance.
The company reported strong year-on-year growth in key financial metrics like operating EBITDA and PAT, along with significant margin expansion, indicating a positive financial performance.
Ind-Swift Laboratories Limited has announced its un-audited standalone financial results for the quarter ended June 30, 2026 (Q1 FY27), reporting significant growth in profitability and margins.
The company's operating EBITDA surged by 2.85 times year-on-year to ₹33.32 crore, with the operating EBITDA margin expanding by 1,258 basis points to 17.91%. Profit After Tax (PAT), excluding exceptional items, stood at ₹24.68 crore, marking a 2.04 times year-on-year increase, while the PAT margin improved by 827 basis points to 13.26%.
Key developments during the quarter include the commercialization of CDMO partnerships with Viatris (USA), Manx (UK), and Arrotex (Australia), which are expected to contribute an incremental ₹200-220 crore in revenue in FY27. Two products, Ibuprofen Sachet for the European market and Macrogol Sachet for the UK and Australia markets, also reached commercialization. The company's global dossier pipeline expanded to over 2,100 filings, with product registrations growing to over 900. Furthermore, the planned upgrade of its Samba manufacturing facility to EU-GMP and PIC/S standards is progressing, aiming to enhance export capabilities and support filings in regulated markets.
Management commentary highlights a strong start to FY27, emphasizing the transformation from an API player to a focused FDF manufacturer. The company is debt-free and aims for a revenue CAGR of over 50% in FY27, with a medium-term target of 20-25% CAGR, supported by EBITDA margin expansion of 600-800 bps.
What to do with a filing like this
Ind-Swift Laboratories Limited filed this with the NSE as a statutory disclosure, categorised under quarterly results. It is a primary document, not a recommendation, and the desk marks it high impact, which is the band that most often changes something.
That call is the part a filing cannot make for you. On RealCase, SEBI-registered research analysts and investment advisers read announcements like this one and turn the ones that matter into actions inside their model portfolios: a change in weight, a hold, or nothing at all. You are not left working out which of the roughly 250 filings published each day needs a response. The portfolio you follow is updated when a filing actually warrants it, with the reason written down.
See the model portfoliosA plain-language summary of a public exchange filing by Ind-Swift Laboratories Limited. Read the original for the full detail.